CPD-2828 is an orally active selective inhibitor of IRE1alpha, with an IC50 value of 1.2 µM. It shows potential for research into endoplasmic reticulum stress-related diseases, such as cancer and neurodegenerative disorders.
Target:
IRE1
* VAT and and shipping costs not included. Errors and price changes excepted
